Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial

Eileen O'Meara, Lisa M Mielniczuk, George A Wells, Robert A deKemp, Ran Klein, Doug Coyle, Brian Mc Ardle, Ian Paterson, James A White, Malcolm Arnold, Matthias G Friedrich, Eric Larose, Alexander Dick, Benjamin Chow, Carole Dennie, Haissam Haddad, Terrence Ruddy, Heikki Ukkonen, Gerald Wisenberg, Bernard Cantin, Philippe Pibarot, Michael Freeman, Eric Turcotte, Kim Connelly, James Clarke, Kathryn Williams, Normand Racine, Linda Garrard, Jean-Claude Tardif, Jean DaSilva, Juhani Knuuti, Rob Beanlands, IMAGE HF investigators, Eileen O'Meara, Lisa M Mielniczuk, George A Wells, Robert A deKemp, Ran Klein, Doug Coyle, Brian Mc Ardle, Ian Paterson, James A White, Malcolm Arnold, Matthias G Friedrich, Eric Larose, Alexander Dick, Benjamin Chow, Carole Dennie, Haissam Haddad, Terrence Ruddy, Heikki Ukkonen, Gerald Wisenberg, Bernard Cantin, Philippe Pibarot, Michael Freeman, Eric Turcotte, Kim Connelly, James Clarke, Kathryn Williams, Normand Racine, Linda Garrard, Jean-Claude Tardif, Jean DaSilva, Juhani Knuuti, Rob Beanlands, IMAGE HF investigators

Abstract

Background: Ischemic heart disease (IHD) is the most common cause of heart failure (HF); however, the role of revascularization in these patients is still unclear. Consensus on proper use of cardiac imaging to help determine which candidates should be considered for revascularization has been hindered by the absence of clinical studies that objectively and prospectively compare the prognostic information of each test obtained using both standard and advanced imaging.

Methods/design: This paper describes the design and methods to be used in the Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) multi-center trial. The primary objective is to compare the effect of HF imaging strategies on the composite clinical endpoint of cardiac death, myocardial infarction (MI), cardiac arrest and re-hospitalization for cardiac causes.In AIMI-HF, patients with HF of ischemic etiology (n = 1,261) will follow HF imaging strategy algorithms according to the question(s) asked by the physicians (for example, Is there ischemia and/or viability?), in agreement with local practices. Patients will be randomized to either standard (SPECT, Single photon emission computed tomography) imaging modalities for ischemia and/or viability or advanced imaging modalities: cardiac magnetic resonance imaging (CMR) or positron emission tomography (PET). In addition, eligible and consenting patients who could not be randomized, but were allocated to standard or advanced imaging based on clinical decisions, will be included in a registry.

Discussion: AIMI-HF will be the largest randomized trial evaluating the role of standard and advanced imaging modalities in the management of ischemic cardiomyopathy and heart failure. This trial will complement the results of the Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy and the PET and Recovery Following Revascularization (PARR-2) trial. The results will provide policy makers with data to support (or not) further investment in and wider dissemination of alternative 'advanced' imaging technologies.

Trial registration: NCT01288560.

Figures

Figure 1
Figure 1
Overall randomization scheme for patients enrolled in Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF).

References

    1. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22:23–45. doi: 10.1016/S0828-282X(06)70237-9.
    1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446. doi: 10.1056/NEJM197112232852601.
    1. Yatteau RF, Peter RH, Behar VS, Bartel AG, Rosati RA, Kong Y. Ischemic cardiomyopathy: the myopathy of coronary artery disease. Natural history and results of medical versus surgical treatment. Am J Cardiol. 1974;34:520–525. doi: 10.1016/0002-9149(74)90121-0.
    1. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, Levine F, Schloss M. Results of coronary artery surgery in patients with poor left ventricular function (CASS) Circulation. 1983;68:785–795. doi: 10.1161/01.CIR.68.4.785.
    1. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, Mock MB, Pettinger M, Robertson TL. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 1990;82:1629–1646. doi: 10.1161/01.CIR.82.5.1629.
    1. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831–836. doi: 10.1016/S0002-9149(83)80141-6.
    1. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001;37:992–997. doi: 10.1016/S0735-1097(01)01109-3.
    1. Tjan TD, Kondruweit M, Scheld HH, Roeder N, Borggrefe M, Schmidt C, Schober O, Deng MC. The bad ventricle revascularization versus transplantation. Thorac Cardiovasc Surg. 2000;48:9–14.
    1. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med. 1985;312:1665–1671. doi: 10.1056/NEJM198506273122603.
    1. Jones RH. Is it time for a randomized trial of surgical treatment of ischemic heart failure? J Am Coll Cardiol. 2001;37:1210–1213. doi: 10.1016/S0735-1097(01)01123-8.
    1. Doenst T, Velazquez EJ, Beyersdorf F, Michler R, Menicanti L, Di Donato M, Gradinac S, Sun B, Rao V. To STICH or not to STICH: we know the answer, but do we understand the question? J Thorac Cardiovasc Surg. 2005;129:246–249. doi: 10.1016/j.jtcvs.2004.07.060.
    1. Louie HW, Laks H, Milgalter E, Drinkwater DC Jr, Hamilton MA, Brunken RC, Stevenson LW. Ischemic cardiomyopathy. Criteria for coronary revascularization and cardiac transplantation. Circulation. 1991;84(5 Suppl):III290–III295.
    1. Kron IL, Flanagan TL, Blackbourne LH, Schroeder RA, Nolan SP. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg. 1989;210:348–352. doi: 10.1097/00000658-198909000-00011. discussion 352–344.
    1. Hochberg MS, Parsonnet V, Gielchinsky I, Hussain SM. Coronary artery bypass grafting in patients with ejection fractions below forty percent. Early and late results in 466 patients. J Thorac Cardiovasc Surg. 1983;86:519–527.
    1. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–1616. doi: 10.1056/NEJMoa1100356.
    1. Fang JC. Underestimating medical therapy for coronary artery disease… Again. N Engl J Med. 2011;364:1671–1673. doi: 10.1056/NEJMe1103414.
    1. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, Leong-Poi H, Miller RM, Nichol G, Freeman M, Bogaty P, Honos G, Hudon G, Wisenberg G, Van Berkom J, Williams K, Yoshinaga K, Graham J. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease--executive summa. Can J Cardiol. 2007;23:107–119. doi: 10.1016/S0828-282X(07)70730-4.
    1. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410. doi: 10.1016/j.cpcardiol.2007.04.001.
    1. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czernin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Schelbert HR, Phelps ME, Maddahi J. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527–533. doi: 10.1016/0002-9149(94)90327-1.
    1. D’Égiodio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, Ruddy TD, DaSilva J, Humen D, Gulenchyn KY, Freeman M, Racine N, Benard F, Hendry P, Beanlands RS. PARR-2 Investigators. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2:1060–1068. doi: 10.1016/j.jcmg.2009.02.017.
    1. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–888. doi: 10.1056/NEJM198604033141405.
    1. Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, Schoenhagen P, Starling RC, Flamm SD, Desai MY. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2:34–44. doi: 10.1016/j.jcmg.2008.09.010.
    1. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98(19 Suppl):II51–II56.
    1. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK, MacIntyre WJ, Thomas JD. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation. 1994;90:2687–2694. doi: 10.1161/01.CIR.90.6.2687.
    1. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol. 1993;22:984–997. doi: 10.1016/0735-1097(93)90407-R.
    1. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–1158. doi: 10.1016/S0735-1097(02)01726-6.
    1. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2) J Am Coll Cardiol. 2007;50:2002–2012. doi: 10.1016/j.jacc.2007.09.006.
    1. Abraham A, Nichol G, Williams K, Garrard L, Guo A, de Kemp RA, Davies RA, Duchesne L, Haddad H, Ruddy TD, Chow B, DaSilva J, Hendry P, Masters R, Higginson L, Beanlands RS. Ottawa-FIVE: FDG in viability evaluation at an experienced center with ready Access to FDG and integration with management teams. J Nucl Med. 2010;51:567–574. doi: 10.2967/jnumed.109.065938.
    1. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–1625. doi: 10.1056/NEJMoa1100358.
    1. Mielniczuk L, Beanlands R. Imaging-guided selection of patients with ischemic heart failure for high risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging. 2012;5:262–270. doi: 10.1161/CIRCIMAGING.111.964668.
    1. Ziadi MC, Garrard L, Beanlands R, Chow B, Hessian R, Ruddy T, Guo A, Williams K, Davies RA, Renaud J, Etele J, DaSilva JN, Ficaro FP, Wisenberg G, Iwanachko M, Marriott C. FDG PET impacts positively management direction and predicts outcomes in a multicentre ‘real world’ setting. Circulation. 2009;120:S349. [abstract]
    1. Liao L, Cabell CH, Jollis JG, Velazquez EJ, Smith WT 4th, Anstrom KJ, Pappas PA, Ryan T, Kisslo JA, Landolfo CK. Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. Am J Cardiol. 2004;93:1275–1279. doi: 10.1016/j.amjcard.2004.01.071.
    1. Sawada SG, Dasgupta S, Nguyen J, Lane KA, Gradus-Pizlo I, Mahenthiran J, Feigenbaum H. Effect of revascularization on longterm survival in patients with ischemic left ventricular dysfunction and a wide range of viability. Am J Cardiol. 2010;106:187–192. doi: 10.1016/j.amjcard.2010.03.014.
    1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
    1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147. doi: 10.7326/0003-4819-139-2-200307150-00013.
    1. O’Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail. 2006;8:63–67. doi: 10.1016/j.ejheart.2005.04.013.
    1. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: A systematic review. Ann Intern Med. 2012;156:785–795. doi: 10.7326/0003-4819-156-11-201203200-00391.
    1. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med. 2007;48:1135–1146. doi: 10.2967/jnumed.106.038851.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren